The validation of in-vivo models aligned with the findings of in-vitro models, supporting the exploration of YGS’s inhibition of tumor immune escape through NF-κB pathway sensitization in CRC stem cells, and its capability to suppress the EMT process in CRC at the tissue level. The gene discussed is NFKB1; the disease is neoplasm.